• Francesc Formiga, Manuel Rubio-Rivas, José María Mora-Luján, Samara Campos Escudero, Rosa Fernandez Madera Martinez, Manuel Mendez-Bailón, Pedro Durán-Del Campo, Andrea Riaño Pérez, Francisco-Javier García-Sánchez, José Nicolás Alcalá-Pedrajas, HernándezSergio ArnedoSAInternal Medicine Department, San Pedro de Logroño Hospital, Logroño, Spain., Almudena Hernández Milian, Ana Latorre Díez, SánchezRicardo GilRGInternal Medicine Department, Universitari I Politècnic La Fe Hospital, Valencia, Spain., Ramon Boixeda, Julio Vicente, Begoña Cortes, Carmen Mella Pérez, EsparteroMaría Esther GuisadoMEGInternal Medicine Department, Infanta Margarita de Cabra Hospital, Cordoba, Spain., CastroJosé LópezJLInternal Medicine Department, Monforte de Lemos, Hospital, Lugo, Spain., Santiago Rodríguez Suárez, Jose F Varona, Ricardo Gomez-Huelgas, Jose Manuel Ramos-Rincón, and SEMI-COVID-19 SEMI-COVID-19 Network.
• Internal Medicine Department, Bellvitge University Hospital, Bellvitge Biomedical Research Institute-IDIBELL, University of Barcelona, L'Hospitalet de Llobregat, 08907, Barcelona, Spain. fformiga@bellvitgehospital.cat.
• Intern Emerg Med. 2022 Apr 1; 17 (3): 761775761-775.

AbstractAcetylsalicylic acid (ASA) is widely used in the treatment and prevention of cardiovascular disorders. Our objective is to evaluate its possible protective role, not only in mortality but also in other aspects such as inflammation, symptomatic thrombosis, and intensive care unit (ICU) admission in hospitalized COVID-19 patients. We realized an observational retrospective cohort study of 20,641 patients with COVID-19 pneumonia collected and followed-up from Mar 1st, 2020 to May 1st, 2021, from the nationwide Spanish SEMI-COVID-19 Registry. Propensity score matching (PSM) was performed to determine whether treatment with ASA affected outcomes in COVID-19 patients. On hospital admission, 3291 (15.9%) patients were receiving ASA. After PSM, 3291 patients exposed to ASA and 2885 not-exposed patients were analyzed. In-hospital mortality was higher in the ASA group (30.4 vs. 16.9%, p < 0.001) in the global sample. After PSM, no differences were found between groups (30.4 vs. 30.3%, p = 0.938). There were no differences in inflammation, symptomatic thrombosis, or ICU admission. In conclusion, ASA intake is not associated with in-hospital mortality or any other health outcome evaluated after applying PSM analysis in a real-world large sample of hospitalized COVID-19 patients.© 2021. Società Italiana di Medicina Interna (SIMI).

15 keywords...

hide…